Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Red Cat Holdings Reports Q3 2025 Revenue Growth of 646% Y/Y Sequential Quarterly Revenue Growth of 200%; Guides Q4 Revenue to 1455% Y/Y; FY 2025 Revenue Guidance to 124% Y/Y, Beating Q3 Revenue Consen
-
AirJoule Technologies (NASDAQ: AIRJ) Announces Third Quarter 2025 Results and Provides Business Update
-
Aterian Reports 2025 Third Quarter Financial Results and Reiterates Guidance
-
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
-
zSpace Reports Third Quarter 2025 Financial Results
-
The Oncology Institute Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance
-
Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2025
-
Flux Power Reports Fiscal Year 2026 First Quarter Financial Results
-
Expion360 Reports Third Quarter 2025 Financial and Operational Results
-
Intchains Group Limited Reports Third Quarter and Nine Months 2025 Financial Results
-
TechPrecision Corporation Reports Fiscal Year 2026 Second Quarter Financial Results
-
Tenon(R) Medical Reports Third Quarter 2025 Financial Results
-
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
-
WidePoint Reports Third Quarter 2025 Financial Results
-
Astera Labs Announces Fourth Quarter 2025 Financial Conference Participation
-
Robinhood Markets, Inc. Reports October 2025 Operating Data
-
TSS Reports Third Quarter 2025 Financial Results
-
Maris-Tech Enters Quantum Navigation Field with Strategic Agreement to Develop Quantum-Based Gyroscope to Replace GPS Navigation
-
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
-
nCino Announces Timing of its Third Quarter Fiscal Year 2026 Financial Results Conference Call
-
ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety
-
Ascertain and The Oncology Institute Co-Develop ‘Touchless’ AI Automation for Oncology Administration
-
Rekor Systems Reports Record Third Quarter 2025 Financial Results
-
BioStem Technologies Reports Third Quarter 2025 Financial Results
-
QuinStreet to Participate at Stephens Investment Conference
-
Credit Acceptance Announces Completion of $500.0 Million Asset-Backed Financing
-
BioStem Technologies Announces Filing of Restated Financial Statements
-
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
-
Luminar Reports Q3’25 Financials
-
VINCI COMPASS REPORTS THIRD QUARTER 2025 EARNINGS RESULTS
-
Vuzix Reports Third Quarter 2025 Results
-
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
-
CleanSpark, Inc. Announces Closing of Upsized $1.15 Billion Zero-Coupon Convertible Notes Offering
-
Clipper Realty Inc. Announces Third Quarter 2025 Results
-
Origin Materials, Inc. Announces Financing and Reports Operating and Financial Results for Third Quarter 2025
-
Co-Diagnostics Reports Third Quarter 2025 Financial Results
-
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
HeartBeam Reports Third Quarter 2025 Results
-
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
-
PRIVATE SAAS COMPANY SURVEY REVEALS AI-DRIVEN TRANSFORMATION AND SUSTAINED OPERATIONAL EXCELLENCE
-
The Metals Company Announces Third Quarter 2025 Corporate Update
-
Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
-
Fossil Group, Inc. Reports Third Quarter 2025 Financial Results
-
Applied Materials Announces Fourth Quarter and Fiscal Year 2025 Results
-
Freehold Royalties Announces Third Quarter 2025 Results
-
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility
-
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
-
Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress
-
Amneal Receives U.S. FDA Approval for Iohexol Injection

